Author + information
- Received August 30, 1993
- Revision received November 8, 1993
- Accepted November 24, 1993
- Published online April 1, 1994.
- ↵∗Address for correspondence: Dr. Jeffrey M. Isner, St. Elizabeth's Hospital, 736 Cambridge Street, Boston, Massachusetts 02135.
The local delilvery of therapeutic agents to the arterial wall represents a new strategy for the treatment of vascular diseases, including restenosis. Approaches for local, intravascular, sitespecific delivery include 1) direct deposition of therapeutic agents into the vessel wall through an intravascular delivery system; 2) systemic administration of inactive agents followed by local activation; and 3) systemic administration of fusion toxins that have a specific affinity to proliferating smooth muscle cells at the angioplasty site. In addition to conventional drugs, new therapeutic agents based on molecular mechanisms, including recombinant genes and antisense oligonucleotides, are now under investigation. Although development of intravascular drug delivery devices, including those tailored to accommodate novel therapeutic agents, offers new treatment options for restenosis and other vascular diseases, certain issues that currently limit the safety and efficacy of these approaches remain to be addressed.
↵1 Dr. Riessen is the recipient of an award from the Deutsche Forschungsgemeinschaft, Tübingen, Germany.
☆ This study was supported in part by an Academic Award in Vascular Medicine (HL 02824) and Grant HL 40518 from the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
- Received August 30, 1993.
- Revision received November 8, 1993.
- Accepted November 24, 1993.